TY - JOUR
T1 - Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: Prevalence and molecular epidemiology
AU - Xanthopoulou, Kyriaki
AU - Peter, Silke
AU - Tobys, David
AU - Behnke, Michael
AU - Dinkelacker, Ariane G.
AU - Eisenbeis, Simone
AU - Falgenhauer, Jane
AU - Falgenhauer, Linda
AU - Fritzenwanker, Moritz
AU - Gölz, Hannah
AU - Häcker, Georg
AU - Higgins, Paul G.
AU - Imirzalioglu, Can
AU - Käding, Nadja
AU - Kern, Winfried V.
AU - Kramme, Evelyn
AU - Kola, Axel
AU - Mischnik, Alexander
AU - Rieg, Siegbert
AU - Rohde, Anna M.
AU - Rupp, Jan
AU - Tacconelli, Evelina
AU - Vehreschild, Maria J.G.T.
AU - Walker, Sarah V.
AU - Gastmeier, Petra
AU - Seifert, Harald
N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: [email protected].
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Objectives: To analyse the rectal carriage rate and the molecular epidemiology of vancomycin-resistant Enterococcus faecium(VREfm) recovered from patients upon hospital admission. Methods: Adult patients were screened at six German university hospitals from five different federal states upon hospital admission for rectal colonization with VREfm between 2014 and 2018. Molecular characterization of VREfm was performed by WGS followed by MLST and core-genome MLST analysis. Results: Of 16350 patients recruited, 263 were colonized with VREfm, with increasing prevalence rates during the 5 year study period (from 0.8% to 2.6%). In total, 78.5% of the VREfm were vanB positive and 20.2% vanA positive, while 1.2% harboured both vanA and vanB. The predominant ST was ST117 (56.7%) followed by ST80 (15%), ST203 (10.9%), ST78 (5.7%) and ST17 (3.2%). ST117/vanB VREfm isolates formed a large cluster of 96 closely related isolates extending across all six study centres and four smaller clusters comprising 13, 5, 4 and 3 isolates each. In contrast, among the other STs inter-regional clonal relatedness was rarely observed. Conclusions: To our knowledge, this is the largest admission prevalence and molecular epidemiology study of VREfm. These data provide insight into the epidemiology of VREfm at six German university hospitals and demonstrate the remarkable inter-regional clonal expansion of the ST117/vanB VREfmclone.
AB - Objectives: To analyse the rectal carriage rate and the molecular epidemiology of vancomycin-resistant Enterococcus faecium(VREfm) recovered from patients upon hospital admission. Methods: Adult patients were screened at six German university hospitals from five different federal states upon hospital admission for rectal colonization with VREfm between 2014 and 2018. Molecular characterization of VREfm was performed by WGS followed by MLST and core-genome MLST analysis. Results: Of 16350 patients recruited, 263 were colonized with VREfm, with increasing prevalence rates during the 5 year study period (from 0.8% to 2.6%). In total, 78.5% of the VREfm were vanB positive and 20.2% vanA positive, while 1.2% harboured both vanA and vanB. The predominant ST was ST117 (56.7%) followed by ST80 (15%), ST203 (10.9%), ST78 (5.7%) and ST17 (3.2%). ST117/vanB VREfm isolates formed a large cluster of 96 closely related isolates extending across all six study centres and four smaller clusters comprising 13, 5, 4 and 3 isolates each. In contrast, among the other STs inter-regional clonal relatedness was rarely observed. Conclusions: To our knowledge, this is the largest admission prevalence and molecular epidemiology study of VREfm. These data provide insight into the epidemiology of VREfm at six German university hospitals and demonstrate the remarkable inter-regional clonal expansion of the ST117/vanB VREfmclone.
UR - http://www.scopus.com/inward/record.url?scp=85091323677&partnerID=8YFLogxK
U2 - 10.1093/jac/dkaa271
DO - 10.1093/jac/dkaa271
M3 - Journal articles
C2 - 32699884
AN - SCOPUS:85091323677
SN - 0305-7453
VL - 75
SP - 2743
EP - 2751
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 10
ER -